FrancophonIA/ELRC3.0 huggingface dataset:
English: Telmisartan is largely bound to plasma protein (> 99.5%), mainly albumin and alpha-1 acid glycoprotein.
Maltese: Telmisartan fil-biċċa l-kbira tiegħu jeħel mal-proteina fil-plażma (>99.5 %), primarjament ma' l-albumina u alpha-1 acid glycoprotein.
English: The mean absolute bioavailability for telmisartan is about 50%.
Maltese: Il-medja tal biodisponibilità assoluta għal telmisartan hi ta' madwar 50%.
English: Al/Al blister packs: 14, 28, 30, 56, 84, 90, 98 and 100 tablets.
Maltese: Daqsijiet tal-pakketti: 14, 28, 30, 56, 84, 90, 98 jew 100 pillola.
English: Reykjavikurvegi 76-78, IS-220 Hafnafjordur ICELAND
Maltese: Reykjavikurvegi 76-78, IS-220 Hafnafjordur L-Islanda
English: Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of > 20 hours.
Maltese: Eliminazzjoni Telmisartan hu kkaratterizzat minn farmakokinetiċi b'decay bi-esponenzjali, b'half-life ta' l-eliminazzjoni terminali ta' >20 siegħa.
English: The incidence of the primary endpoint was similar in the telmisartan (16.7%) and ramipril (16.5%) groups.
Maltese: L-inċidenza tar-riżultat aħħari primarju kienet simili fil gruppi ta' telmisartan (16.7%) u ramipril (16.5%).
English: Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Maltese: Ir-reazzjonijiet avversi ġew ikklassifikati skond kategoriji ta' frekwenza bl-użu tal-konvenzjoni li ġejja: komuni ħafna (≥1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000), rari ħafna (<1/10,000).
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 30.09.2010
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 30.09.2010
English: Eosinophilia, thrombocytopenia
Maltese: Eosinofilja, tromboċitopenija
English: The adjusted DBP changes from baseline were -8.4 (1.5) mm Hg, -4.5 (1.6) mm Hg and -3.5 (2.1) mm Hg respectively.
Maltese: (1.5) mm Hg, -4.5 (1.6) mm Hg u -3.5 (2.1) mm Hg rispettivament.
English: The hazard ratio for telmisartan vs. ramipril was 1.01 (97.5% CI 0.931.10, p (non-inferiority) = 0.0019 at a margin of 1.13).
Maltese: Il-proporzjon ta' periklu għal telmisartan vs. ramipril kien ta' 1.01 (97.5% CI 0.93 - 1.10, p (non-inferjorità) = 0.
English: Cumulative urinary excretion is < 1% of dose.
Maltese: L-eliminazzjoni kumulattiva fl-awrina hi ta' <1% tad-doża.
English: Pruritus, hyperhidrosis, rash
Maltese: Hakk, iperidrosi, raxx
English: The main risk factors for hyperkalaemia to be considered are: - Diabetes mellitus, renal impairment, age (> 70 years)
Maltese: - Dijabete mellitus, indeboliment renali, età (> 70 sena)
English: Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5% CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Maltese: Instab li telmisartan kien effettiv bl-istess mod bħal ramipril fir-riżultat aħħari sekondarju speċifikat minn qabel ta' mewt kardjovaskulari, infart mijokardijaku mhux fatali, u puplesija mhux fatali [0.99 (97.5% CI 0.90 - 1.08), p (non-inferjorità) = 0.0004], ir-riżultat aħħari primarju fl-istudju ta' referenza HOPE (The Heart Outcomes Prevention Evaluation Study), li kien investiga l-effett ta' ramipril vs. plaċebo.
English: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Second and third trimesters of pregnancy (see sections 4.4 and 4.6) - Biliary obstructive disorders - Severe hepatic impairment
Maltese: - Sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe wieћed mill-eċċipjenti elenkati fis-sezzjoni 6.1 - It-tieni u t-tielet trimestru tat-tqala (ara sezzjonijiet 4.4 u 4.6) - Disturbi ostruttivi biljari - Indeboliment sever epatiku
English: Patients were randomized to one of the three following treatment groups: telmisartan 80 mg (n = 8542), ramipril 10 mg (n = 8576), or the combination of telmisartan 80 mg plus ramipril 10 mg (n = 8502), and followed for a mean observation time of 4.5 years.
Maltese: Il-pazjenti ntgħażlu b'mod każwali f'wieħed mit-tliet gruppi ta' kura li ġejjin: telmisartan 80 mg (n =8542), ramipril 10 mg (n = 8576), jew it-taħlita ta' telmisartan 80 mg flimkien ma' ramipril 10 mg (n= 8502), u li kienu segwiti għal medja ta' żmien ta' osservazzjoni ta' 4.5 snin.
English: Manufacturer Actavis Hf.
Maltese: Actavis Hf.
English: Interstitial lung disease4
Maltese: Mard interstizjali tal-pulmun4
English: PUREN Pharma GmbH & Co. KG Tel.: +49-89-558-9090
Maltese: KG Tel.: +49-89-558-9090
English: What Telmisartan Actavis contains - The active substance is telmisartan.
Maltese: X'fih Telmisartan Actavis - Is-sustanza attiva hi telmisartan.
English: Reykjavíkurvegur 76-78, IS-220 Hafnarfjördur Iceland
Maltese: Reykjavíkurvegur 78, IS-220 Hafnafjördur L-Islanda
English: 220 Hafnarfjörður Iceland
Maltese: Hafnarfjörður L-Islanda
English: Pack sizes:
Maltese: Mhux komuni:
English: Tfno.
Maltese: A.U.
English: TRANSCEND randomized ACE-I intolerant patients with otherwise similar inclusion criteria as ONTARGET to telmisartan 80 mg (n = 2954) or placebo (n = 2972), both given on top of standard care.
Maltese: TRANSCEND għażel b'mod każwali pazjenti li kienu intolleranti għal ACE-I u li mill-bqija kellhom kriterji tal-inklużjoni li kienu simili bħal dawk ta' ONTARGET għal telmisartan 80 mg (n=2954) jew plaċebo (n=2972), it-tnejn mogħtija b'mod addizzjonali mal-kura standard.
English: In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70% vs. 0.49% [RR 1.43 (95% confidence interval 1.00- 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33%) vs. patients taking placebo (0.16%) [RR 2.07 (95% confidence interval 1.14 3.76)].
Maltese: Fil-prova "Kors ta' Prevenzjoni Biex Tevita b'Mod Effettiv Puplesiji Oħrajn" (Prevention Regimen For Effectively avoiding Second Strokes - PRoFESS), f'pazjenti li għandhom 50 sena jew aktar, li dan l-aħħar kellhom puplesija, kienet osservata żieda fl-inċidenza ta' sepsis għal telmisartan meta mqabbelmalplaċebo, 0.70 % vs. 0.49 % [RR 1.43 (95% intervall ta' kunfidenza 1.00 - 2.06)]; l-inċidenza ta' każijiet ta' sepsis fatali żdiedet għal pazjenti li kienu qed jieħdu telmisartan (0.33 %) vs. pazjenti li kienu qed jieħdu l-plaċebo (0.16 %) [RR 2.07 (95% intervall ta' kunfidenza 1.14 - 3.76)].
English: - The other ingredients are magnesium stearate, croscarmellose sodium, mannitol, povidone,
Maltese: - Is-sustanzi l-oħra huma are magnesium stearate, croscarmellose sodium, mannitol, povidone, potassium hydroxide pellets.
English: Corticosteroids (systemic route) Reduction of the antihypertensive effect.
Maltese: Kortikosterojdi (rotta sistemika)
English: INFORMATION IN BRAILLE Telmisartan Actavis 40 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Telmisartan Actavis 40mg
English: 4.6 Fertility, pregnancy and lactation
Maltese: .6 Fertilita', tqala u treddigħ Tqala
English: Total plasma clearance (Cltot) is high (approximately 1,000 ml/min) compared with hepatic blood flow (about 1,500 ml/min).
Maltese: It tneħħija totali mill-plażma (Cltot) hi għolja (madwar 1,000 ml/min) meta mqabbla mal-fluss tad-demm epatiku (madwar 1,500 ml/min).
English: After adjustment for age group effects mean SBP changes from baseline (primary objective) were -14.5 (1.7) mm Hg in the telmisartan 2 mg/kg group, -9.7 (1.7) mm Hg in the telmisartan 1 mg/kg group, and -6.0 (2.4) in the placebo group.
Maltese: Wara aġġustament għall-effetti tal-grupp ta' età, il medja ta' tibdil tal-SBP mil-linja bażi (oġġettiv primarju) kienet ta' -14.5 (1.7) mm Hg fil-grupp ta' telmisartan 2 mg/kg, -9.7 (1.7) mm
English: Al/Al blisters: Pack sizes: 14, 28, 30, 56, 84, 90, 98 or 100 tablets.
Maltese: Folji tal-aluminju/aluminju: 14, 28, 30, 56, 84, 90, 98 u 100 pillola Kontenituri tal-pilloli: 30 u 250 pillola.
English: Other medicines and Telmisartan Actavis
Maltese: Mediċini oħra u Telmisartan Actavis
English: INFORMATION IN BRAILLE Telmisartan Actavis 80 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Telmisartan Actavis 80mg
English: Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Maltese: Dejta disponibbli attwalment hi deskritta fis-sezzjonijiet 5.1 u 5.2 imma l-ebda rakkomandazzjoni dwar il pożoloġija ma tista' tingħata.
English: HDPE container with LDPE lid and desiccant Pack sizes: 30 or 250 tablets.
Maltese: Kontenitur tal-HDPE b'għatu maghmul minn LDPE Daqsijiet tal-pakketti: 30 jew 250 pillola.
English: INFORMATION IN BRAILLE Telmisartan Actavis 20 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Telmisartan Actavis 20mg
English: Fertility In preclinical studies, no effects of telmisartan on male and female fertility were observed.
Maltese: Fertilità Fi studji kliniċi, l-ebda effetti ta' telmisartan fuq il-fertilità maskili u femminili kienu osservati.
English: Common side effects (may affect up to 1 in 10 people): Low blood pressure (hypotension) in users treated for reduction of cardiovascular events.
Maltese: Effetti sekondarji komuni (jistgħu jaffettwaw sa persuna 1 minn kull 10):Pressjoni tad-demm baxxa (ipotensjoni) fl-utenti kkurati għal tnaqqis ta' avvenimenti kardjovaskulari
English: Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
Maltese: Dejta minn provi kliniċi wriet li imblokk doppju tas-sistema renin-angiotensin-aldosterone (RAAS) permezz tal-użu ikkombinat ta' inibituri ta' ACE, imblokkaturi tar-riċettur ta' angiotensin II jew aliskiren hija assoċjata ma' frekwenza ogħla ta' avvenimenti avversi bħal pressjoni baxxa, iperkalemija u tnaqqis fil-funzjoni renali (inkluż insuffiċjenza akuta renali) meta mqabbel mal-użu ta' sustanza waħda li taġixxi fuq RAAS (ara sezzjonijiet 4.3, 4.4 u 5.1).
English: 1,2,3,4: for further descriptions, please see sub-section 4 ”Description of selected adverse reactions”.
Maltese: 1,2,3,4: għal deskrizzjonijiet addizzjonali, jekk jogħġbok ara sottosezzjoni “Deskrizzjoni ta' reazzjonijiet avversi magħżula”.
English: ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Maltese: ALTITUDNI (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) kien studju mfassal biex jittestjaw il-benefiċċju li jiżdied aliskiren ma' terapija standard ta' inibitur ta' ACE jew imblokkatur tar-riċettur ta' angiotensin II f'pazjenti b'dijabete mellitus tip 2 u mard kroniku renali, mard kardjovaskulari, jew it-tnejn.
English: When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0-∞) of telmisartan varies from approximately 6% (40 mg dose) to approximately 19% (160 mg dose).
Maltese: Meta telmisartan jittieħed ma' l-ikel, it-tnaqqis taż-żona taħt il-kurva tal-konċentrazzjoni tal-plażma-żmien (AUC0-∞) ta' telmisartan tvarja minn madwar 6% (doża ta' 40 mg) sa madwar 19% (doża ta' 160 mg).
English: Pharmacokinetic objectives included the determination of the steady-state of telmisartan in children and adolescents, and investigation of age-related differences.
Maltese: L-objettivi farmakokinetiċi kienu jinkludu d determinazzjoni tal-istat fiss ta' telmisartan fit-tfal u adolexxenti, u investigazzjoni ta' differenzi relatati mal-età.
English: Pregnancy:
Maltese: Sintomi:
English: There was no evidence of mutagenicity and relevant clastogenic activity in in vitro studies and no evidence of carcinogenicity in rats and mice.
Maltese: Ma kien hemm l-ebda evidenza ta' mutaġeniċità u ta' attività klastoġenika rilevanti fi studji in vitro, u lebda evidenza ta' karċinoġeneċità fil-firien u fil-ġrieden.
English: Anaphylactic reaction , hypersensitivity Metabolism and nutrition disorders Uncommon:
Maltese: Disturbi fil-metaboliżmu u n-nutrizzjoni Mhux komuni:
English: The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.
Maltese: L-użu ta' prodotti mediċinali li jaffettwaw is-sistema renin-angiotensin-aldosterone, jista' jikkawża l iperkalemija.
English: 1,2,3,4: for further descriptions, please see sub-section 4 “Description of selected adverse reactions”
Maltese: 1,2,3,4: għal deskrizzjonijiet addizzjonali, jekk jogħġbok ara sottosezzjoni “Deskrizzjoni ta' reazzjonijiet avversi magħżula”
English: The concomitant use of Telmisartan Actavis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and
Maltese: L-użu fl-istess ħin ta' Telmisartan Actavis flimkien ma' prodotti li jkun fihom aliskiren huwa kontraindikat f'pazjenti b'dijabete mellitus jew b'indeboliment tal-kliewi (GFR < 60 ml/min/1.73 m2) (ara sezzjonijiet 4.5 and 5.1).
English: Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased
Maltese: (proteina fid-demm), żieda fil-livelli tal-uric acid, ta' enzimi epatiċi jew ta' creatine phosphokinase fid demm.
English: The antihypertensive efficacy of telmisartan is comparable to that of agents representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril).
Maltese: L-effikaċja anti-ipertensiva ta' telmisartan hi komparabbli ma' dik ta' mediċini li jirrappreżentaw kategoriji oħrajn ta' prodotti mediċinali anti-ipertensivi (dan intwera fi provi kliniċi li qabblu telmisartan ma' amlodipine, atenolol, enalapril,
English: Abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting Dry mouth, stomach discomfort, dysgeusia
Maltese: Uġigħ addominali, dijarea, dispepsja, gass, rimettar Ħalq xott, skonfort fl-istonku, disgewżja
English: Medicinal products or therapeutic class of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
Maltese: Prodotti mediċinali jew klassijiet terapewtiċi ta' prodotti mediċinali li jistgħu jikkawżaw l-iperkalemija huma sostituti tal-melħ li fihom il-potassium, dijuretiċi li ma jneħħux potassium, inibituri ta' ACE, antagonisti tar-riċettur ta' angiotensin II, prodotti mediċinali mhux sterojdi kontra l-infjammazzjoni (NSAIDs, li jinkludu inibituri COX-2 selettivi), eparina, immunosoppressuri (cyclosporin jew tacrolimus), u trimethoprim.
English: Telmisartan Actavis 40 mg tablets Telmisartan
Maltese: Telmisartan Actavis 40 mg pilloli telmisartan
English: Telmisartan Actavis 20 mg tablets Telmisartan
Maltese: Telmisartan Actavis 20 mg pilloli Telmisartan
English: Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).
Maltese: Imblokk doppju ta' RAAS permezz tal-użu ikkombinat ta' inibituri ta' ACE, imblokkaturi tar-riċettur ta' angiotensin II jew aliskiren huwa għalhekk mhux rakkomandat (ara sezzjonijiet 4.5 u 5.1).
English: Telmisartan Actavis 80 mg tablets Telmisartan
Maltese: Telmisartan Actavis 80 mg pilloli Telmisartan
English: The blood pressure lowering effects of two doses of telmisartan were assessed in 76 hypertensive, largely overweight patients aged 6 to < 18 years (body weight ≥ 20 kg and ≤ 120 kg, mean 74.6 kg), after taking telmisartan 1 mg/kg (n = 29 treated) or 2 mg/kg (n = 31 treated) over a four-week treatment period.
Maltese: L-effetti li jbaxxu l-pressjoni tad-demm taż-żewġ dożi ta' telmisartan ġew evalwati f'76 pazjenti bi pressjoni għolja, li fil-biċċa l-kbira tagħhom kellhom piż żejjed, li kellhom minn 6 sa < 18-il sena (piż talġisem ta' ≥ 20 kg u ≤ 120 kg, medja ta' 74.6 kg), wara li ħadu telmisartan 1 mg/kg (n = 29 ikkurati) jew 2 mg/kg (n = 31 ikkurati) fuq perjodu ta' kura ta' erba' ġimgħat.
English: In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
Maltese: angiotensin II u mediċini li jinibixxu cyclo-oxygenase, jista' jirriżulta f'deterjorament addizzjonali talfunzjoni renali, li jinkludi l-possibbiltà ta' insuffiċjenza akuta renali, li normalment tkun riversibbli.
English: By inclusion the presence of secondary hypertension was not investigated.
Maltese: Bl-inklużjoni il-preżenza ta' pressjoni għolja sekondarja ma ġietx investigata.
English: Reduction of cardiovascular morbidity in adults with: - manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or - type 2 diabetes mellitus with documented target organ damage
Maltese: - mard kardjovaskulari aterotrombotiku sintomatiku (storja medika ta' mard koronarju tal-qalb, puplesija, jew mard arterjali periferali) jew - dijabete mellitus ta' tip 2 bi ħsara dokumentata tal-organu fil-mira
English: (It is also better to avoid Telmisartan Actavis in early pregnancy - see pregnancy section.)
Maltese: Telmisartan Actavis kmieni fit-tqala - ara ssezzjoni dwar it-tqala.)
English: Telmisartan Actavis contains the active substance telmisartan which belongs to a class of medicines known as angiotensin II receptor antagonists.
Maltese: Telmisartan Actavis fih is-sustanza attiva telmisartan li jagħmel parti minn klassi ta' mediċini magħrufa bħala antagonisti tar-riċetturi ta' angiotensin II.
English: Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants.
Maltese: barbiturati, narkotiċi jew antidepressivi.
English: The overall incidence of adverse reactions reported with telmisartan was usually comparable to placebo (41.4% vs 43.9%) in placebo controlled trials in patients treated for hypertension.
Maltese: L-inċidenza ta' reazzjonijiet avversi rrappurtati kienetġeneralment komparabbli mal-plaċebo (41.4% vs
English: The effect of Telmisartan Actavis may be reduced when you take NSAIDs (non steroidal anti-inflammatory drugs, e.g. aspirin or ibuprofen) or corticosteroids.
Maltese: L-effetti ta' Telmisartan Actavis jistgħu jitnaqqsu meta tieħu NSAIDs (mediċini mhux sterojdi kontra linfjammazzjoni, eż. aspirina jew ibuprofen) jew kortikosterojdi.
English: Serious adverse drug reactions include anaphylactic reaction and angioedema which may occur rarely (≥1/10,000 to <1/1,000), and acute renal failure.
Maltese: Reazzjonijiet avversi serji jinkludu anġjoedema u reazzjoni anafilattika u jistgħu jseħħu b'mod rari (≥1/10,000 sa <1/1,000), u insuffiċjenza akuta tal-kliewi.
English: Hepatic function abnormal / liver disorder
Maltese: Funzjoni epatika anormali / disturb tal-fwied
English: How to store Telmisartan Actavis
Maltese: Telmisartan Actavis.
English: - Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors (angiotensinconverting enzyme inhibitors, to treat high blood pressure), angiotensin II receptor antagonists (to treat high blood pressure), NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin (a medicine for thinning the blood), immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
Maltese: • Mediċini li jistgħu jżidu il-livelli tal-potassium fid-demm bħal sostituti tal-melħ li fihom ilpotassium, dijuretiċi li ma jneħħux potassium (ċerti ‘pilloli tal-awrina'), inibituri ACE (inibituri tal-enzimi li jikkonvertu angiotensin, biex tikkura l-pressjoni tad-demm għolja), antagonisti tar riċettur ta' angiotensin II (biex tikkura l-pressjoni tad-demm għolja), NSAIDs (mediċini mhux sterojdi kontra linfjammazzjoni, eż. aspirina jew ibuprofen), eparina (mediċina biex traqqaq iddemm), immunosoppressivi (eż. cyclosporin jew tacrolimus), u l-antibijotiku trimethoprim.
English: This is confirmed by trough to peak ratios consistently above 80% seen after doses of 40 and 80 mg of telmisartan in placebo controlled clinical studies.
Maltese: Dan hu kkonfermat mill-proporzjonijiet bejn il-livelli l-aktar baxxi imqabbla ma' l-ogħla livelli, li kienu aktar minn 80% b'mod konsistenti, osservati wara li ngħataw dożi ta' 40 u 80 mg ta' telmisartan fi provi kliniċi b'telmisartan ikkontrollati bi plaċebo.
English: Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.
Maltese: Mewt kardjovaskulari u puplesija t-tnejn kienu numerikament aktar frekwenti fil-grupp ta' aliskiren milli fil-grupp tal-plaċebo, u avvenimenti avversi u avvenimenti avversi serji ta' interess (iperkalimja, pressjoni baxxai u disfunzjoni renali) kienu rrappurtati b'mod aktar frekwenti fil-grupp ta' aliskiren milli fil-grupp tal-plaċebo.
English: Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Maltese: Uġigħ fil-griżmejn, sinuses injfammati, riħ komuni), tnaqqis fiċ-ċelluli tad-demm ħomor (anemija), livelli għolja tal-potassju, diffikulta biex torqod, tħossok imdejjaq (dipressjoni), ħass ħażin (sinkope), sensazzjoni li kollox qed idur bik (sturdament), taħbit tal-qalb b'rata baxxa (bradikardija), pressjoni baxxa (ipotensjoni) fl-utenti kkurati għal pressjoni għolja tad-demm, sturdament meta tqum bil-wieqfa (ipotensjoni ortostatika), qtugħ ta' nifs, sogħla, uġigħ addominali, dijarea, skonfort fl-addome, nefħa, rimettar, ħakk, żieda fl-għaraq, raxx, uġiegħ fid-dar, bugħawwieġ, uġiegħ fil-muskoli (majalġja), indeboliment tal-kliewi inkluż insuffiċjenza tal-kliewi f'daqqa, uġiegħ fis-sider, sensazzjoni ta‘ dgħufija, u livelli ta' kreatinina għolja fid-demm.
English: - Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
Maltese: • Stenosi tal-arterji renali (tidjiq tal-vini/arterji lejn kilwa waħda jew lejn iż-żewġ kliewi).
English: VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
Maltese: ALTITUDNI (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)